The systemic amyloidoses: An overview

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 107-137

  Falk, Rodney H ^a,b   Skinner, Martha ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

AMYLOIDOSIS; BIOSYNTHESIS; GENETICS; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

AMYLOID; AMYLOIDOSIS; HUMANS; PROGNOSIS;

EID: 0033630225     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Cohen AS CE: Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183:1202-1203, 1959.
2. Shirahama T CA: High resolution electron microscopic analysis of the amyloid fibril. J Cell Biol 333:679-708, 1967.
3. Bonar L, Cohen AS, Skinner MM: Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 131(4):1373-1375, 1969.
4. Glenner GG TW, Harada M, Isersky C, et al: Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 172:1150-1151, 1971.
5. Benditt E, Eriksen N, Hermodson M, et al: The major proteins of human and monkey amyloid substance: Common properties including unusual N-terminal amino acid sequences. FEBS Lett 19:169-173, 1971.
6. Costa PP, Figueira AS, Bravo FR: Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A 75(9):4499-4503, 1978.
7. Westermark P: The pathogenesis of amyloidosis: Understanding general principles [comment]. Am J Pathol 152(5):1125-1127, 1998.
8. Solomon A, Frangione B, Franklin EC: Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 70(2):453-460, 1982.
9. Perfetti V, Ubbiali P, Vignarelli MC, et al: Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 91(8):2948-2954, 1998.
10. Stevens FJ, Myatt EA, Chang CH, et al: A molecular model for self-assembly of amyloid fibrils: Immunoglobulin light chains. Biochemistry 34(34):10697-10702, 1995.
11. Hurle MR, Helms LR, Li L, et al: A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 91(12):5446-5450, 1994.
12. Solomon A, Weiss DT: Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis) [review]. Amyloid 2(4):269-279, 1995.
13. Schiffer M: Molecular anatomy and the pathological expression of antibody light chains [comment]. Am J Pathol 148(5):1339-1344, 1996.
14. Kluve-Beckerman B, Dwulet FE, Benson MD: Human serum amyloid A. J Clin Invest 82:1670-1675, 1988.
15. Yamada T, Kluve-Beckerman B, Liepnieks JJ, et al: Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1226:323-329, 1994.
16. Westermark GT, Engstrom U, Westermark P: The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 182(1):27-33, 1992.
17. Snow AD, Kisilevsky R: Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab Invest 53(1):37-44, 1985.
18. Johan K, Westermark G, Engstrom U, et al: Acceleration, of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. Proc Natl Acad Sci U S A 95(5):2558-2563, 1998.
19. Gustavsson A, Engstrom U, Westermark P: Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 144(6):1301-1311, 1994.
20. Serpell LC, Goldsteins G, Dacklin I, et al: The edge strand hypothesis: Prediction and test of a mutational hot-spot on the transthyretin molecule associated with Fap amyloidogenesis. Amyloid 3(2):75-85, 1996.
21. Kelly JW, Lansbury PT: A chemical approach to elucidate the mechanism of transthyretin and beta-protein amyloid fibril formation [review]. Amyloid 1(3):186-205, 1994.
22. Westermark P, Sletten K, Johansson B, et al: Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 87(7):2843-2845, 1990.
23. Genschel J, Haas R, Propsting MJ, et al: Apolipoprotein A-I induced amyloidosis. FEBS Letters 430(3):145-149, 1998.
24. Rader DJ, Gregg RE, Meng MS, et al: In vivo metabolism of a mutant apolipoprotein, apoA-Howa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 33(5):755-763, 1992.
25. Walsh M: A novel amyloidogenic variant of apolipoprotein A1: Implications for a conformational change leading to cardiomyopathy. Am J Pathol 154:11-14, 1999.
26. Asl LH, Liepnieks JJ, AsI KH, et al: Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1 [see comments]. Am J Pathol 154(1):221-227, 1999.
27. Booth DR, Sunde M, Bellotti V, et al: Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis [see comments]. Nature 385(6619):787-793, 1997.
28. Eriksson S, Janciauskiene S, Merlini G: The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. J Intern Med 237(2):143-149, 1995.
29. Peterson SA, Klabunde T, Lashuel HA, et al: Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A 95(22):12956-12960, 1998.
30. Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses [see comments]. N Engl J Med 337(13):898-909, 1997.
31. Kyle RA, Linos A, Beard CM, et al: Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]. Blood 79(7):1817-1822, 1992.
32. Jacobson DR, Pastore R, Pool S, et al: Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 98(2):236-238, 1996.
33. Jacobson DR, Pastore RD, Yaghoubian R, et al: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans [see comments]. N Engl J Med 336(7):466-473, 1997.
34. Jacobson DR, Pan T, Kyle RA, et al: Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Hum Mutat 9(1):83-85, 1997.
35. Jacobson DR, Ittmann M, Buxbaum JN, et al: Transthyretin Ile 122 and cardiac amyloidosis in African-Americans: 2 case reports. Tex Heart Inst J 24(1):45-52, 1997.
36. Hawkins PN, Aprile C, Capri G, et al: Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 25(7):701-708, 1998.
37. Shah VB, Phatak AM, Shah BS, et al: Renal amyloidosis - a clinicopathologic study. Indian J Pathol Microbiol 39(3):179-185, 1996.
38. Schena FP, Pannarale G, Carbonara MC: Clinical and therapeutic aspects of renal amyloidosis. Nephrol Dial Transplant 11 9:63S-86S, 1996.
39. Kyle RA, Gertz MA, Greipp PR, et al: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine [see comments]. N Engl J Med 336(17):1202-1207, 1997.
40. Looi LM, Cheah PL: Histomorphological patterns of renal amyloidosis: A correlation between histology and chemical type of amyloidosis. Hum Pathol 28(7):847-849, 1997.
41. Skinner M, Anderson J, Simms R, et al: Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100(3):290-298, 1996.
42. Hachulla E, Maulin L, Deveaux M, et al: Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: From diagnosis to prognosis. Am J Med 101(1):77-87, 1996.
43. Sanders PW: Renal involvement in plasma cell dyscrasias. Curr Opin Nephrol Hypertens 2(2):246-252, 1993.
44. Saile R, Deveaux M, Hachulla E, et al: Iodine-123-labelled serum amyloid P component scintigraphy in amyloidosis. Eur J Nucl Med 20(2):130-137, 1993.
45. Dubrey SW, Cha K, Anderson J, et al: The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91(2):141-157, 1998.
46. Reisinger J, Dubrey SW, Lavalley M, et al: Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 30(4):1046-1051, 1997.
47. Falk RH, Plehn JF, Deering T, et al: Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 59(5):418-422, 1987.
48. Dubrey SW, Bilazarian S, LaValley M, et al: Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J 134(6):994-1001, 1997.
49. Libbey CA, Skinner M, Cohen AS: Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Inten Med 143(8):1549-1552, 1983.
50. Duston MA, Skinner M, Shirahama T, et al: Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience. Am J Med 82(3):412-414, 1987.
51. Gertz MA, Li CY, Shirahama T, et al: Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Intern Med 148(4):929-933, 1988.
52. Masouye I: Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: An analysis of 100 cases. Am J Dermatopathol 19(1):41-45, 1997.
53. Ropper A, Gorson K: Current concepts: Neuropathies associated with paraproteinemia. N Engl J Med 338:1601-1607, 1998.
54. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998;104(3):232-237, 1998.
55. Gemmi F, Miliani A, Bergesio F, et al: Functional study of autonomic neuropathy in primary (AL) amyloidosis. Amyloid 3(3):167-172, 1996.
56. Reyners AK, Hazenberg BP, Haagsma EB, et al: The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid 5(3):193-199, 1998.
57. Gertz MA, Kyle RA: Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 60(6):655-660, 1996.
58. Ii K, Hizawa K, Nunomura S, et al: Systemic amyloid myopathy - light-microscopic and fine-structural study of the skeletal muscles with histochemical and immunohistochemical study of amyloid. Acta Neuropathol 64(2):114-121, 1984.
59. Jennekens FG, Wokke JH: Proximal weakness of the extremities as main feature of amyloid myopathy. J Neurol Neurosurg Psychiatry 50(10):1353-1358, 1987.
60. Prayson RA: Amyloid myopathy: Clinicopathologic study of 16 cases. Hum Pathol 29(5):463-468, 1998.
61. Traynor AE, Gertz MA, Kyle RA: Cranial neuropathy associated with primary amyloidosis. Ann Neurol 29(4):451-454, 1991.
62. Utz JP, Swensen SJ, Gertz MA: Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 124(4):407-413, 1996.
63. Celli BR, Rubinow A, Cohen AS, et al: Patterns of pulmonary involvement in systemic amyloidosis. Chest 74(5):543-547, 1978.
64. Menke DM, Kyle RA, Fleming CR, et al: Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 68(8):763-767, 1993.
65. Tada S, Iida M, Yao T, et al: Intestinal pseudo-obstruction in patients with amyloidosis: Clinicopathologic differences between chemical types of amyloid protein [see comments]. Gut 34(10):1412-1417, 1993.
66. Legge DA, Carlson HC, Wollaeger EE: Roentgenologic appearance of systemic amyloidosis involving gastrointestinal tract. Am J Roentgenol Radium Ther Nucl Med 110(2):406-412, 1970.
67. Carlson HC, Breen JF: Amyloidosis and plasma cell dyscrasias: Gastrointestinal involvement. Sem Roentgenol 21(2):128-138, 1986.
68. Mohan V, Kemp JA, Lewine HE, et al: Diffuse mesenteric amyloidosis. Dig Dis Sci 42(5):1079-1082, 1997.
69. Chopra S, Rubinow A, Koff RS, et al: Hepatic amyloidosis. A histopathologic analysis of primary (AL) and secondary (AA) forms. Am J Pathol 115(2):186-193, 1984.
70. Lovat LB, Persey MR, Madhoo S, et al: The liver in systemic amyloidosis: Insights from 1231 serum amyloid P component scintigraphy in 484 patients. Gut 42(5):727-734, 1998.
71. Gertz MA, Kyle RA: Hepatic amyloidosis: Clinical appraisal in 77 patients. Hepatology 25(1):118-121, 1997.
72. Ades CJ, Strutton GM, Walker NI, et al: Spontaneous rupture of the liver associated with amyloidosis. J Clin Gastroenterol 11(1):85-87, 1989.
73. Kitchens CS: The anatomic basis of purpura. Progress in Hemostasis and Thrombosis 5:211-244, 1980.
74. Yood RA, Skinner M, Rubinow A, et al: Bleeding manifestations in 100 patients with amyloidosis. JAMA 249(10):1322-1324, 1983.
75. Segalov E, Gibson J, Joshua DE, et al: Primary amyloidosis co-presenting with cervical and massive intra-abdominal lymphadenopathy. Leuk Lymphoma 19(5-6):519-520, 1995.
76. Hammersley N, Moos KF: Primary amyloidosis causing macroglossia and respiratory symptoms. Br J Oral Maxillofac Surg 23(6):445-449, 1985.
77. Burroughs EI, Aronson AE, Duffy JR, et al: Speech disorders in systemic amyloidosis. Br J Disord Commun 26(2):201-206, 1991.
78. Hunt SJ, Caserio RJ, Abell E: Primary systemic amyloidosis causing diffuse alopecia by telogen arrest (letter). Arch Dermatol 127(7):1067-1068, 1991.
79. Wheeler GE, Barrows GH: Alopecia universalis. A manifestation of occult amyloidosis and multiple myeloma. Arch Dermatol 117(12):815-816, 1981.
80. Vestey JP, Tidman MJ, McLaren KM: Primary nodular cutaneous amyloidosis - long-term follow-up and treatment. Clin Exp Dermatol 19(2):159-162, 1994.
81. Hagari Y, Mihara M, Hagari S: Nodular localized cutaneous amyloidosis: Detection of monoclonality of infiltrating plasma cells by polymerase chain reaction. Br J Dermatol 135(4):630-633, 1996.
82. el-Reshaid KA, Hakim AA, Hourani HA, et al: Endocrine abnormalities in patients with amyloidosis. Ren Fail 16(6):725-730, 1994.
83. Rich MW: Hypothyroidism in association with systemic amyloidosis. Head Neck 17(4):343-345, 1995.
84. Harvey CJ, Gower PE, Hawkins PN, et al: Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure. Nephrol Dial Transplant 10(7):1237-1239, 1995.
85. Arik N, Tasdemir I, Karaaslan Y, et al: Subclinical adrenocortical insufficiency in renal amyloidosis. Nephron 56(3):246-248, 1990.
86. Danby P, Harris KP, Williams B, et al: Adrenal dysfunction in patients with renal amyloid. Q J Med 76(281):915-922, 1990.
87. Rafal RB, Jennis R, Kosovsky PA, et al: MRI of primary amyloidosis. Gastrointest Radiol 15(3):199-201, 1990.
88. Handelsman DJ, Yue DK, Turtle JR: Hypogonadism and massive testicular infiltration due to amyloidosis. J Urol 129(3):610-612, 1983.
89. Benson MD, Uemichi T: Transthyretin amyloidosis [review]. Amyloid 3(1):44-56, 1996.
90. Staunton H, Davis MB, Guiloff RJ, et al: Irish (Donegal) amyloidosis is associated with the transthyretin ALA60 (Appalachian) variant. Brain 114(Pt 6):2675-2679, 1991.
91. Benson MD, Wallace MR, Tejada E, et al: Hereditary amyloidosis: Description of a new American kindred with late onset cardiomyopathy. Appalachian amyloid. Arthritis Rheum 30(2):195-200, 1987.
92. Dubrey SW, Cha K, Skinner M, et al: Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes [see comments]. Heart 78(1):74-82, 1997.
93. Gorevic PD, Prelli FC, Wright J, et al: Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: Immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest 83(3):836-843, 1989.
94. Nichols WC, Liepnieks JJ, Snyder EL, et al: Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE-122). J Lab Clin Med 117(3):175-180, 1991.
95. Jacobson DR, Gorevic PD, Buxbaum JN: A homozygous transthyretin variant associated with senile systemic amyloidosis: Evidence for a late-onset disease of genetic etiology. Am J Hum Gen 47(1):127-136, 1990.
96. Saraiva MJ, Sherman W, Marboe C, et al: Cardiac amyloidosis: Report of a patient heterozygous for the transthyretin isoleucine 122 variant. Scand J Immunol 32(4):341-346, 1990.
97. McCarthy RE 3rd, Kasper EK: A review of the amyloidoses that infiltrate the heart. Clin Cardiol 21(8):547-552, 1998.
98. Kiuru S: Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide [review]. Amyloid 5(1):55-66, 1998.
99. Maury CP: Gelsolin-related amyloidosis. Identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin. J Clin Invest 87(4):1195-1199, 1991.
100. Booth DR, Tan SY, Booth SE, et al: Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 97(12):2714-2721, 1996.
101. Booth DR, Tan SY, Booth SE, et al: A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 88(10):695-702, 1995.
102. Uemichi T, Liepnieks JJ, Gertz MA, et al: Fibrinogen A alpha chain Leu 554: An African-American kindred with late onset renal amyloidosis. Amyloid 5(3):188-192, 1998.
103. Uemichi T, Liepnieks JJ, Benson MD: Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest 93(2):731-736, 1994.
104. Benson MD, Liepnieks J, Uemichi T, et al: Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain [see comments]. Nat Genet 3(3):252-255, 1993.
105. Harrison RF, Hawkins PN, Roche WR, et al: "Fragile" liver and massive hepatic haemorrhage due to hereditary amyloidosis. Gut 38(1):151-152, 1996.
106. Pepys MB, Hawkins PN, Booth DR, et al: Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362(6420):553-557, 1993.
107. Sveinbjornsdottir S, Blondal H, Gudmundsson G, et al: Progressive dementia and leucoencephalopathy as the initial presentation of late onset hereditary cystatin-C amyloidosis. Clinicopathological presentation of two cases. J Neurol Sci 140(1-2):101-108, 1996.
108. Roos RA, Haan J, Van Broeckhoven C: Hereditary cerebral hemorrhage with amyloidosis - Dutch type: A congophilic angiopathy. An overview. Ann N Y Acad Sci 640:155-160, 1991.
109. Connors LH, Ericsson T, Skare J, et al: A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing. Biochim Biophys Acta 1407(3):185-192, 1998.
110. Pucci A, Wharton J, Arbustini E, et al: Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity. J Pathol 165(3):235-241, 1991.
111. Looi LM: Isolated atrial amyloidosis: A clinicopathologic study indicating increased prevalence in chronic heart disease. Hum Pathol 24(6):602-607, 1993.
112. Takemura G, Takatsu Y, Doyama K, et al: Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 31(4):754-765, 1998.
113. Takahashi M, Hoshii Y, Kawano H, et al: Ultrastructural evidence for the formation of amyloid fibrils within cardiomyocytes in isolated atrial amyloid. Amyloid 5(1):35-42, 1998.
114. Cornwell GG, Murdoch WL, Kyle RA, et al: Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618-623, 1983.
115. Linke RP: Immunohistochemical identification and cross reactions of amyloid fibril proteins in senile heart and amyloid in familial polyneuropathy. Lack of reactivity with cerebral amyloid in Alzheimer's disease. Clin Neuropathol 1(4):172-182, 1982.
116. Cornwell GG, Westermark P, Natvig JB, et al: Senile cardiac amyloid: Evidence that fibrils contain a protein immunologically related to prealbumin. Immunology 44(3):447-452, 1981.
117. Kyle RA, Spittell PC, Gertz MA, et al: The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 101(4):395-400, 1996.
118. Gertz MA, Kyle RA: Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 70(4):246-256, 1991.
119. Heering P, Hetzel R, Grabensee B, et al: Renal transplantation in secondary systemic amyloidosis. Clin Transpl 12(3):159-164, 1998.
120. Gratacos J, Orellana C, Sanmarti R, et al: Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 24(5):912-915, 1997.
121. Ferhanoglu B, Erzin Y, Baslar Z, et al: Secondary amyloidosis in the course of idiopathic myelofibrosis. Leukemia Res 21(9):897-898, 1997.
122. Sarkar B, Singh S, Suri M, et al: Secondary amyloidosis following juvenile chronic arthritis. Indian Pediatr 33(2):125-127, 1996.
123. Tsuda S, Maeyama Y, Yamamoto N, et al: Secondary amyloidosis complicating arthropathic psoriasis. Clin Exp Dermatol 21(2):141-144, 1996.
124. Alabi ZO, Ojo OS, Odesanmi WO: Secondary amyloidosis in chronic osteomyelitis. Int Orthop 15(1):21-22, 1991.
125. Ben-Chetrit E, Levy M: Colchicine prophylaxis in familial Mediterranean fever: Reappraisal after 15 years. Sem Arthritis Rheum 20(4):241-246, 1991.
126. Zemer D, Livneh A, Pras M, et al: The kidney in familial Mediterranean fever. Contrib Nephrol 102:187-197, 1993.
127. Livneh A, Zemer D, Langevitz P, et al: Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 37(12):1804-1811, 1994.
128. Samuels J, Aksentijevich I, Torosyan Y, et al: Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 77(4):268-297, 1998.
129. Perfetti V, Garini P, Vignarelli MC, et al: Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica 80(5):409-415, 1995.
130. Kyle RA: Sequence of testing for monoclonal gammopathies - serum and urine assays. Arch Pathol Lab Med 123(2):114-118, 1999.
131. Gertz MA, Greipp PR, Kyle RA: Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. J Lab Clin Med 118(1):33-39, 1991.
132. Grunewald K, Sepp N, Weyrer K, et al: Gene rearrangement studies in the diagnosis of primary systemic and nodular primary localized cutaneous amyloidosis. J Invest Dermatol 97(4):693-696, 1991.
133. Pasternak S, White VA, Gascoyne RD, et al: Monoclonal origin of localised orbital amyloidosis detected by molecular analysis. Br J Ophthalmol 80(11):1013-1017, 1996.
134. Theberge R, Connors L, Skinner M, et al: Characterization of transthyretin mutants from serum using immunoprecipitation, HPLC/electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 71(2):452-459, 1999.
135. Rocken C, Schwotzer EB, Linke RP, et al: The classification of amyloid deposits in clinicopathological practice. Histopathology 29(4):325-335, 1996.
136. Linke RP, Gartner HV, Michels H: High-sensitivity diagnosis of AA amyloidosis using Congo red and immunohistochemistry detects missed amyloid deposits. J Histochem Cytochem 43(9):863-869, 1995.
137. Falk RH, Lee VW, Rubinow A, et al: Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 51(5):826-830, 1983.
138. Falk RH, Lee VW, Rubinow A, et al: Cardiac technetium-99m pyrophosphate scintigraphy in familial amyloidosis. Am J Cardiol 54(8):1150-1151, 1984.
139. Aprile C, Marinone G, Saponaro R, et al: Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 22(12):1393-1401, 1995.
140. Hawkins PN, Myers MJ, Lavender JP, et al: Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1(8600):1413-1418, 1988.
141. Hawkins PN: Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci 87(3):289-295, 1994.
142. Hawkins PN, Pepys MB: Imaging amyloidosis with radiolabelled SAP (editorial). Eur J Nucl Med 1995;22(7):595-599.
143. Gertz MA, Falk RH, Skinner M, et al: Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 55(13 Pt 1):1645, 1985.
144. Gertz MA, Skinner M, Connors LH, et al: Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 55(13 Pt 1):1646, 1985.
145. Pollak A, Falk RH: Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104(2):618-620, 1993.
146. Dubrey S, Falk RH: Heart transplantation in AL amyloidosis. Amyloid 2(4):284-287, 1995.
147. Hall R, Hawkins PN: Cardiac transplantation for AL amyloidosis [clinical conference]. BMJ 309(6962):1135-1137, 1994.
148. Pelosi F Jr, Capehart J, Roberts WC: Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. Am J Cardiol 79(4):532-535, 1997.
149. Dubrey S, Simms RW, Skinner M, et al: Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol 76(10):739-741, 1995.
150. Hosenpud JD, DeMarco T, Frazier OH, et al: Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 84(5 Suppl):III338-343, 1991.
151. Shapiro DL, Spiera H: Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report [see comments]. Arthritis Rheum 38(12):1851-1854, 1995.
152. Crowley S, Feinfeld DA, Janis R: Resolution of nephrotic syndrome and lack of progression of heroin-associated renal amyloidosis. Am J Kidney Dis 13(4):333-335, 1989.
153. Mandelstam P, Simmons DE, Mitchell B: Regression of amyloid in Crohn's disease after bowel resection. A 19-year follow-up. J Clin Gastroenterol 11(3):324-326, 1989.
154. Ravid M, Shapira J, Kedar I, et al: Regression of amyloidosis secondary to granulomatous ileitis following surgical resection and colchicine administration. Acta Hepato-Gastroenterol 26(6):513-515, 1979.
155. Kyle RA, Greipp PR, Garton JP, et al: Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 79(6):708-716, 1985.
156. Comenzo RL, Vosburgh E, Falk RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91(10):3662-3670, 1998.
157. Comenzo RL, Vosburgh E, Simms RW, et al: Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 88(7):2801-2806, 1996.
158. Comenzo RL, Sanchorawala V, Fisher C, et al: Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 104(3):553-559, 1999.
159. Gianni L, Bellotti V, Gianni AM, et al: New drug therapy of amyloidoses: Resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 86(3):855-861, 1995.
160. Merlini G, Anesi E, Garihi P, et al: Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update (letter). Blood 93(3):1112-1113, 1999.
161. Dubrey SW, Davidoff R, Skinner M, et al: Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 64(1):74-80, 1997.
162. Stangou AJ, Hawkins PN, Heaton ND, et al: Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: Implications for amyloid fibrillogenesis. Transplantation 66(2):229-233, 1998.